Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to -$21.4 million.

  • Gyre Therapeutics' Net Cash Flow rose 1213.65% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 962.01%. This contributed to the annual value of -$21.4 million for FY2024, which is 348.18% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Net Cash Flow of -$21.4 million as of FY2024, which was down 348.18% from $8.6 million recorded in FY2023.
  • Over the past 5 years, Gyre Therapeutics' Net Cash Flow peaked at $15.0 million during FY2020, and registered a low of -$48.1 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$21.4 million (2024), whereas its average is -$20.3 million.
  • Per our database at Business Quant, Gyre Therapeutics' Net Cash Flow spiked by 194.32% in 2020 and then tumbled by 444.23% in 2022.
  • Gyre Therapeutics' Net Cash Flow (Yearly) stood at $15.0 million in 2020, then dropped by 6.70% to $14.0 million in 2021, then tumbled by 444.23% to -$48.1 million in 2022, then spiked by 117.93% to $8.6 million in 2023, then slumped by 348.18% to -$21.4 million in 2024.